IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down

IDO Don’ts: After Immunotherapy Failure, Experts Say Slow Down

Source: 
Xconomy
snippet: 

One year ago, on the eve of the yearly American Society of Clinical Oncology conference, a new class of drugs called IDO inhibitors seemed poised to become the next big thing in cancer care. They were a top choice to combine with the powerful but limited immunotherapies that have emerged this decade to fight many types of cancer.